Acute Pain Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Acute Pain Market Trends and Insights

Rising Surgical And Procedural Volumes

Surgical and procedural volumes continue to expand across developed and emerging healthcare systems. U.S. total hip arthroplasty volume rose 177%, while total knee arthroplasty volume rose 156% during the 2 decades to 2019, and procedure backlogs continued to support demand after the pandemic period. Higher-acuity procedures are moving into ambulatory settings, which increases the need for effective pain control after same-day discharge. Patients recovering at home cannot rely on extended inpatient monitoring, so providers need longer-acting and practical regimens. The 2026 American Society of Anesthesiologists guidelines^{[1]American Society of Anesthesiologists, “2026 American Society of Anesthesiologists Practice Guidelines for Perioperative Pain Management,” American Society of Anesthesiologists} recommend regional analgesia and surgical-site infiltration within multimodal perioperative care. This guidance supports broader use and more consistent protocol design across the acute pain market and across the acute pain treatment pathway.

Opioid-Sparing Treatment Adoption

The move away from opioid-centered treatment has become tied to clinical practice and payment requirements. CMS Measure 477 encourages clinicians to document multimodal pain management during the perioperative period. A 2026 systematic review found that adding a second multimodal component reduced 24-hour opioid use by 5.2 mg oral morphine equivalents and reduced pain scores at 4 hours. This evidence makes the case for protocols that combine established analgesics with regional or local options. The U.S. Centers for Disease Control and Prevention^{[2]Centers for Disease Control and Prevention, “Guideline Recommendations and Guiding Principles for Prescribing Opioids,” Centers for Disease Control and Prevention}recommends the lowest effective opioid dose for the shortest necessary duration for acute pain. As opioid use falls, the acute pain market can still gain value because replacement therapies often carry higher prices than generic opioids, making reimbursement design important across the acute pain market.

Expansion Of Ambulatory And Same-Day Surgery

Ambulatory surgery changes the type of analgesia providers need during recovery. Same-day discharge makes prolonged intravenous opioid treatment less suitable and places greater value on therapies that cover the first 24 to 72 hours at home. Extended-release local anesthetics and bupivacaine and meloxicam combinations are designed for this period. This care model also supports regional blocks and local infiltration at the procedure site. Hospital purchasing teams therefore assess products by their fit with discharge pathways as well as their direct clinical effect. The acute pain market benefits when a treatment can support safe recovery without requiring another visit or a longer stay, which raises the value of products that fit the acute pain market in outpatient care.

Innovation For Underserved Care Settings

Rural emergency departments, community trauma clinics, and pre-hospital services often have limited access to intravenous and regional techniques. These settings need analgesics that are simple to use and suitable for acute trauma care. Medical Developments International’s Penthrox inhaler illustrates a non-opioid option intended for trauma pain where intravenous access is not available. Topical, inhaled, oral, and single-application formulations may also serve patients who cannot use conventional hospital-based treatment. Sports injuries and emergency cases widen demand beyond scheduled surgical procedures. This part of the acute pain market requires companies to match product design with local approvals, affordable pricing, and primary care distribution, giving the acute pain market a wider base than surgical care alone.

Opioid Safety Scrutiny And Prescribing Restrictions

Tighter opioid controls create a mixed outcome for the acute pain market. The CDC guidance limits duration and dose, while state policies can cap the supply prescribed for acute pain. These measures reduce the role of opioids but do not automatically move every patient to premium non-opioid products. Many providers and payers still rely on lower-cost NSAIDs and acetaminophen when budgets are limited. Research cited in the supplied material reported that 50% of tertiary-care patients had inadequate pain relief, while more than 80% experienced moderate-to-severe postoperative pain within 2 weeks of discharge. The result can be fragmented treatment, with patients remaining undertreated while payers resist higher-cost alternatives.

High Cost Of Novel Non-Opioid Therapies

Novel products face a difficult economic test in routine care. Vertex set the wholesale acquisition cost of JOURNAVX at USD 15.50 per 50 mg tablet when the product launched in 2025. The American College of Surgeons noted that bundled payment structures can make lower-cost NSAIDs or opioids more likely choices after surgery. Medicare's separate payment for qualifying non-opioid pain drugs began in January 2025, but the policy is scheduled to expire at the end of 2027 unless extended. This uncertainty can affect long-term purchasing commitments by hospitals and ambulatory surgery centers. In resource-limited countries, generic NSAIDs and acetaminophen are likely to retain a central role because branded alternatives remain costly.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Drug Class: NSAIDs Remain Established While Local Anesthetics Gain Use

NSAIDs held 34.5% of revenue in 2025, making them the largest drug class in the acute pain market. Their position reflects broad use in postoperative, musculoskeletal, dental, and over-the-counter care. They are supported by long clinical experience and availability across hospital, retail, and digital channels. A 2025 study^{[3]“Optimal Multimodal Analgesia Combinations to Reduce Postoperative Pain and Opioid Use Following Non-Cardiac Surgery,” Regional Anesthesia and Pain Medicine} found that NSAIDs and dexamethasone reduced postoperative pain scores and opioid consumption more effectively than acetaminophen within multimodal regimens. That evidence can influence hospital committees that still treat acetaminophen as the default non-opioid option.

Local anesthetics are forecast to record the fastest growth at a 6.2% CAGR through 2031. Liposomal bupivacaine is used more often in orthopedic, reconstructive, and spine procedures. Pacira reported 7% year-over-year EXPAREL volume growth in the first quarter of 2026. Acetaminophen remains a widely used adjunct across age groups, while opioids remain necessary in high-severity postoperative and acute oncology settings. Gabapentinoids, ketamine, dexmedetomidine, and corticosteroids are increasingly used as components of combination protocols rather than as stand-alone choices.

By Pain Type And Clinical Application: Postoperative Care Leads While Sports Pain Expands

Postoperative pain accounted for 31.8% of revenue in 2025, reflecting its role in nearly every surgical specialty. It is often the most treatment-intensive application because pain may continue after a patient leaves the facility. This creates demand across hospital and retail channels. Procedure-specific protocols also make postoperative care important for label development and hospital formulary decisions. The acute pain industry continues to depend on surgical applications because they combine predictable demand with closely managed treatment pathways. These applications remain central to the acute pain market.

Musculoskeletal and sports pain is projected to grow at a 6.8% CAGR through 2031. Participation in sports, workplace injuries, and emergency trauma care are extending use beyond planned surgical settings. Trauma and injury pain remains underpenetrated because emergency department treatment is often insufficient. The supplied research cited findings that 74% of emergency department patients still reported moderate-to-severe pain at discharge despite receiving medication. Dental pain remains a high-volume indication for OTC products, while renal colic, sickle cell crises, and migraines have their own treatment needs and specialist pathways.

By Route Of Administration: Oral Products Lead While Injectables Address Surgical Needs

Oral products held 57.4% of revenue in 2025, the largest route in the acute pain market. Their lead comes from OTC analgesics, outpatient prescriptions, and self-administration. Oral non-opioid medicines such as JOURNAVX can fit outpatient care without requiring facility administration. The format also works well with retail and online pharmacy distribution. Cost and convenience remain important reasons for its broad use.

Injectable and parenteral products are forecast to grow at a 6.5% CAGR through 2031. Intraoperative nerve blocks, intravenous NSAID infusion, and extended-release injections support opioid-sparing care. Pacira’s PCRX-2002, a ropivacaine hydrogel candidate, entered Phase 2 development in 2026 for postsurgical pain. Topical and transdermal products also have a role in sports and musculoskeletal care, especially for patients who need to limit systemic NSAID exposure. Inhaled and rectal options remain niche but can be relevant where oral or intravenous access is impractical.

By Distribution Channel: Hospitals Lead While Online Access Broadens

Hospital pharmacies held 48.6% of revenue in 2025, showing the importance of inpatient and perioperative treatment. Hospitals handle injectable products, branded local anesthetics, and complex surgical pain protocols. These settings generate more revenue per treatment than many OTC purchases. Their purchasing decisions also determine whether newer products reach clinicians. The acute pain industry remains divided between consumer brands in retail care and specialty products used in hospitals.

Online pharmacies are forecast to grow at a 6.4% CAGR through 2031. Direct-to-consumer OTC sales and telehealth prescription services support this change. The DEA extended certain telemedicine prescribing flexibilities through December 31, 2026. Large consumer healthcare brands can benefit from their existing digital marketing and distribution capabilities. Specialty companies with hospital-administered products are less exposed to this channel, which reinforces the different competitive models across the acute pain market.

Geography Analysis

North America held 42.1% of global revenue in 2025, giving the region the largest acute pain market share. The region benefits from high procedure volumes, established hospital purchasing systems, and early adoption of multimodal protocols. Separate Medicare Part B payment for qualifying non-opioid pain drugs began in January 2025 and reduced a financial barrier in hospital outpatient departments and ambulatory surgery centers. Pacira^{[4]Pacira BioSciences, “Pacira BioSciences Reports First Quarter 2026 Financial Results,” Pacira BioSciences} announced in July 2026 that UnitedHealthcare provides separate reimbursement for EXPAREL across outpatient settings. Canada and Mexico add volume, but uptake of novel branded non-opioids remains more limited than in the United States.

Europe contributes meaningful demand through Germany, the United Kingdom, France, Italy, and Spain. National assessment and reimbursement processes can delay uptake of new analgesics even when clinical evidence is available. This environment favors established NSAIDs and acetaminophen until new therapies complete local reviews. Regional analgesia and multimodal care are increasingly consistent with European enhanced recovery practice. The Middle East and Africa have a two-tier profile, with Gulf Cooperation Council countries more able to adopt premium therapies while many sub-Saharan markets rely on generic medicines.

Asia-Pacific is projected to grow at a 6.3% CAGR through 2031, the fastest regional rate in the acute pain market. China and India are the main growth engines because of expanding healthcare infrastructure, manufacturing capacity, and large patient populations. Japan’s aging population supports demand for non-opioid pain treatment, although regulatory reviews can slow new product access. Pacira entered an agreement with LG Chem in January 2026 to pursue EXPAREL commercialization in South Korea and Thailand. South America has rising demand for effective OTC products, but budget pressure and currency volatility limit adoption of premium therapies.